Cargando…
Antidiabetic Drugs in NAFLD: The Accomplishment of Two Goals at Once?
Non-Alcoholic Fatty Liver Disease (NAFLD) is the most common cause of chronic liver disease in Western countries, accounting for 20–30% of general population and reaching a prevalence of 55% in patients with type 2 diabetes mellitus (T2DM). Insulin resistance plays a key role in pathogenic mechanism...
Autores principales: | Tacelli, Matteo, Celsa, Ciro, Magro, Bianca, Giannetti, Aurora, Pennisi, Grazia, Spatola, Federica, Petta, Salvatore |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6316860/ https://www.ncbi.nlm.nih.gov/pubmed/30413050 http://dx.doi.org/10.3390/ph11040121 |
Ejemplares similares
-
The Burden of Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease: Screening Issue and Future Perspectives
por: Pennisi, Grazia, et al.
Publicado: (2019) -
Pharmacological Therapy of Non-Alcoholic Fatty Liver Disease: What Drugs Are Available Now and Future Perspectives
por: Pennisi, Grazia, et al.
Publicado: (2019) -
Ion Mobility Spectrometry after Chromatography—Accomplishments, Goals, Challenges
por: Hill, Herbert H., et al.
Publicado: (1988) -
Systems metabolic engineering as an enabling technology in accomplishing sustainable development goals
por: Yang, Dongsoo, et al.
Publicado: (2017) -
The National Institute on Alcohol Abuse and Alcoholism: Past Accomplishments and Future Goals
por: Gordis, Enoch
Publicado: (1995)